₹350.0
-2.26% today
· 30d -3.82%
as of 2026-09-04
Price · Daily Candles
“INDRAMEDCO: Q4 Profit Growth Slows Amidst Broader Downtrend, Analyst Target Undimmed.”
INDRAMEDCO, with a market cap of ₹3407.0 Cr, saw quarterly profit growth slow to +1.68% YoY despite a +9.31% YoY revenue increase for Q4 2026. The stock trades at a TTM PE of 18.55, significantly below the sector average, and has declined 29.55% over the last six months, approaching its 52-week low.
BULL CASE
+Annual net profit grew by 14.06% YoY to ₹184.0 Cr in FY26, following a 5-year CAGR of 139.52%.
+Trading at a TTM P/E of 18.55, INDRAMEDCO is considerably cheaper than sector peers like APOLLOHOSP (PE 82.13) and MAXHEALTH (PE 67.07).
+Profitability is strong, with a profit margin of 12.39% and a current FCF yield of 3.16%.
+Despite recent price weakness, the sole analyst covering the stock has a mean target of ₹550.0, implying significant upside from the current price of ₹375.0, with zero target dispersion.
BEAR CASE
−Q4 2026 net profit growth significantly decelerated to 1.68% YoY, even as operating profit growth stalled at 0.25% YoY.
−The stock has seen substantial price depreciation, down 29.55% over the last six months and is only 9.65% above its 52-week low of ₹342.0.
−FII shareholding decreased by 0.29% QoQ to 2.44% in Q4 2026.
−Technical indicators are bearish, with a moderate bearish MACD signal and the stock trading near its 52-week low.
⟳ What Changed
₹ Latest Earnings · Q ending 2026-06-30
REVENUE
₹406 Cr
+11.26% YoY
NET PROFIT
₹56 Cr
+8.53% YoY
OPM
21.28%
-0.24pp YoY
EPS
₹6.09
PE 18.55
Intrinsic value · DCF: N/A — ML model predicts severe Δ FCF compression (h1=-44.6%, h2=-44.9%, h3=-42.0% of mktcap), driving projected FCF negative by year 3 despite healthy current FCF. Treating as forecast outlier rather than reporting a misleading ₹0 valuation. Use the Strategy Fit and ML sections instead.
◇ Sector Position
INDRAMEDCO's TTM PE of 18.55 is substantially lower than most peers like APOLLOHOSP (82.13) and MAXHEALTH (67.07), but its ROCE of 14.44% lags behind ASTERDM's 103.54% and NH's 22.72%.
PEERPEROCE %
INDRAMEDCO18.55—
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒
52
SCORE / 100
Overall
6-axis composite of the sections below.
Performance
UNDERPERFORMER
20
Valuation
CHEAP
75
Growth
STEADY
59
Profitability
HIGH
75
Technicals
WEAK
30
Risk
MODERATE
50
Key Stats
TTM PE
18.55
P/B
5.17
52W HIGH
₹640.85
OFF HIGH
-45.39%
DIV YIELD
1.24%
MKT CAP
₹3180 Cr
◉ Active Signals
MACDBearish-2.0564
RSI(14)Bearish34.94
Near 52W LowBearish2.34
Street Consensus
1 analyst₹550.0
mean target
Low ₹550.0Now ₹350.0High ₹550.0
⧉ Strategy Fit 🔒